Jean-Claude Jelsch

CellProthera SAS operates as a holding company with interests in medical studies on heart diseases. The firm focuses on the development of a stem cell therapy for the regeneration of myocardial tissue allowing the prevention of chronic heart failure following acute myocardial infarct by injecting a cell graft containing antilogous adult stem cells sampled directly from the patient. The company was founded by Philippe H?non in April 2008 and is headquartered in Mulhouse, France.

CellProthera SAS operates as a holding company with interests in medical studies on heart diseases. The firm focuses on the development of a stem cell therapy for the regeneration of myocardial tissue allowing the prevention of chronic heart failure following acute myocardial infarct by injecting a cell graft containing antilogous adult stem cells sampled directly from the patient. The company was founded by Philippe H?non in April 2008 and is headquartered in Mulhouse, France.

CellProthera SAS operates as a holding company with interests in medical studies on heart diseases. The firm focuses on the development of a stem cell therapy for the regeneration of myocardial tissue allowing the prevention of chronic heart failure following acute myocardial infarct by injecting a cell graft containing antilogous adult stem cells sampled directly from the patient. The company was founded by Philippe H?non in April 2008 and is headquartered in Mulhouse, France.

CellProthera SAS operates as a holding company with interests in medical studies on heart diseases. The firm focuses on the development of a stem cell therapy for the regeneration of myocardial tissue allowing the prevention of chronic heart failure following acute myocardial infarct by injecting a cell graft containing antilogous adult stem cells sampled directly from the patient. The company was founded by Philippe H?non in April 2008 and is headquartered in Mulhouse, France.

CellProthera SAS operates as a holding company with interests in medical studies on heart diseases. The firm focuses on the development of a stem cell therapy for the regeneration of myocardial tissue allowing the prevention of chronic heart failure following acute myocardial infarct by injecting a cell graft containing antilogous adult stem cells sampled directly from the patient. The company was founded by Philippe H?non in April 2008 and is headquartered in Mulhouse, France.